3 Critical Goals Every New Medical Device Should Aim For

Interview with Doug Evans, CEO of Lungpacer Medical

We recently caught up with the CEO of Lungpacer Medical, Doug Evans. Lungpacer is developing a novel therapeutic solution that preserves the strength of the diaphragm muscle for critically-ill patients on mechanical ventilation.

Doug is also a board member of Intact Vascular, which was acquired by Philips, and the former COO of Kensey Nash. He’s a medtech veteran with decades of experience launching startups, developing products, working with payers & regulators, and commercializing novel technologies. Today, we’re going to discuss all these topics, and hear more about Lungpacer’s impressive technology.

But first, here’s a bit more about Doug Evans and his background:

Doug started his career at GE in business development, and later joined Kensey Nash when it was just a startup with fewer than ten employees. As COO, he led Kensey’s growth to over 400 employees, across the span of 20 years, before they were acquired by Royal DSM. After that, Doug began working with other startups like Intact Vascular and TELA Bio.

Doug holds a master's degree in electrical engineering and photonics from Penn, as well as an MBA. He knows the medtech startup landscape better than just about anyone, and we’re grateful he’s sharing his perspective with the Medsider community.

Premium Members Only

Premium Members Only

You don't have access to this post, but if you become a premium member, you'll be able to see the whole thing, including many other exclusive benefits.

You don't have access to this post, but if you become a premium member, you'll be able to see the whole thing, including many other exclusive benefits.

You May Like These Articles

Medsider Premium

Become a premium member and unlock access to exclusive Medsider benefits.

Medsider Mentors

Medsider Mentors

Medsider Playbooks

Medsider Playbooks

Playbook

A Guide to Widespread Adoption in Medtech

In medtech, developing novel, impactful technology is often just the starting line. The real race begins when you try to integrate your solution into the often-resistant healthcare system – a hurdle that has tripped up countless promising companies. Here are the key strategies and lessons from five veterans in the medtech space on how to overcome this hurdle.

Copyright © Medsider 2024 • All rights reserved.

Subscribe

Sign In

Suggest a Guest

Copyright © Medsider 2024 • All rights reserved.

Subscribe

Sign In

Suggest a Guest

Copyright © Medsider 2024 • All rights reserved.

Subscribe

Sign In

Suggest a Guest